Simon Kraler

Honored to receive the Research Prize of @SwissCardio &talking about #risk in #acs. Many thanks to the whole team behind the curtain @K_Stellos @RaberLorenz @liberale_luca @JuzZTeeNa @RichiKobza @ucl @HerzstiftungCH @cmc_uzh @Ste_MNS @UZH_en @CotSwiss @EJCI_News @TomLuscher

New mechanisms, new targets. Emerging cardiovascular–metabolic risk pathways open the door to innovative therapeutic opportunities. Read more in #EHJ. doi.org/10.1093/eurhea… #metagolism #atherosclerosis #dyslipidemia #cardiotwitter @ESC_Journals @escardio

#cardiology #cardiovascular #cardiotwitter #cardioX #AI @BrighamResearch @MountSinaiHeart

Meta-analysis of 5 RCTs (n=4,964): Adding antiplatelet therapy to anticoagulation in chronic coronary syndrome patients offers no benefit for MI, stroke, or MACE—but doubles major bleeding risk. Net clinical outcome significantly worse with dual pathway... ahajrnls.org/4rvd68A

Great discussions, fresh ideas, and strong team spirit today at the ESC Office in Brussels! 🇪🇺🫀 We met to shape upcoming scientific initiatives, strengthen collaborations, and plan future educational and research activities. Exciting projects ahead — stay tuned! @escardio

With 561 references, this article—published in Nature Reviews Cardiology—is among the most comprehensive reviews of the pathophysiology, biomarkers, and therapeutic strategies addressing residual risk in coronary artery disease. Read more at bit.ly/4q3Fain

This #InternationalEducationDay, we celebrate the young cardiovascular professionals shaping the future of cardiology through the ESC Young Community. As active contributors, they’re driving tomorrow’s knowledge through: 🔹 Innovative educational resources 🔹 The ESC 365 Young Track 🔹 The ESC Mentoring Platform Discover how young voices are making an impact 👉 ow.ly/5WQN50Y1E7u #ESCardioEd #ESCYoung #ESC365 @jozinetm @slumberbell @_antocannata @cfcamm @mrubini @martha_kyriakou @KralerSimon @CharlesFauvel @eromerodorta @aleks_gasecka @SMosteoru @ManningerMartin @JohannesGrand

In February, the first episode of viroLOGICAL will go online. In this weekly podcast, I will talk about virology, different viruses, vaccines etc. Trailer: ➡️ Spotify: open.spotify.com/show/2LxUpjumK… ➡️ Apple Podcasts: podcasts.apple.com/at/podcast/vir… ➡️ Podigee: virological.podigee.io

#HF merits careful diagnosis and management, in particular in patients with cancer!🫀 #HFrEF is not the only manifestations🔍preserved ejection fraction is common and sometimes tricky to diagnose🕵️‍♂️ Read the latest consensus from #ESCardioOnco @escardio

Residual risk in acute coronary syndromes is increasigly debated. The junctional protein associated with coronary artery disease might play a relevant role according to a new study. doi.org/10.1093/eurhea… #ACS #cardiotwitter, @ESC_Journals, @escardio

Check out our study with @liberale_luca on a novel therapeutic target for coronary artery disease: #JCAD @CarboneF82 @DavideRamoni @HemostasisToday @escardio @TomLuscher @EHJACVCEiC @cescobruno @UZH_en

🫀 Despite modern therapies, residual cardiovascular risk remains high. JCAD emerges as a promising target to address residual CV risk in patients with acute coronary syndrome. 📖 Read our publication in European Heart Journal 🚀 @ehj_ed @escardio academic.oup.com/eurheartj/arti…

In this first randomized trial of treatment strategies in #MINOCA, a stratified treatment, based on comprehensive diagnostic assessment and aetiology-guided therapy, led to a significant improvement in angina. Read the results of the PROMISE trial just published in #EHJ 👉 ow.ly/UM7h50Xkcnr @RoccoMontone @ehj_ed #TCT2025

ha let’s question what we do everyday everyday. congrats to the authors on this brilliant study!!

Happy to contribute to: Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990-2023⁩ - Africa at the epicentre of CVD ⁦⁦@AfricaEuroCoRE⁩ ⁦⁦@UofGSii⁩ jacc.org/doi/10.1016/j.…

🛑NARRATIVE REVIEW~Wiley Online Library Central nervous system involvement in cardiac amyloidosis: Redefining the heart‐brain axis 🔗 doi.org/10.1111/eci.70… ✍️🏻DomenicoMarioGiamundo  GiulianoCassataro   StefanoMinistrini  SimonF.Stämpfli @Ste_MNS @unitorvergatamed @ospedalegiglio @unipa_it @cmc_uzh @KantonsspitalLU #amyloidosis #cardiacamyloidosis #cognitivedecline #ischemicstroke #neurodegeneration #systemicamyloidosis

Advancements in Lipid-Lowering Therapies: Targeting Key Mechanisms in Lipid and Lipoprotein Metabolism! Read the news in #EHJ! academic.oup.com/eurheartj/adva… #lipoproteins #EHJ #cardiotwitter @ESC_journals @escardio

The #EAPCI26 Summit is a gathering of leaders and rising talents in interventional cardiology and related specialties. The call for science is now open! Submit your work and be among the first to influence practice. 📅 Abstracts - 16 October | Clinical cases - 23 October bit.ly/4peXrd7 #EAPCI @EAPCIPresident

Abstract submission deadline extended! You now have until 15 September to submit your abstract for CBFH 2025. Don’t miss this chance to share your work and join us in Naples, Italy (26–28 November) for the Biennial Meeting of the ESC Working Groups on Cellular Biology of the Heart and Myocardial Function ow.ly/3ZbH50WRezG #CVD #cellularbiology

Public health protects us all — often quietly, behind the scenes. Now, it needs our voices. Eight former CDC directors and I, spanning Presidents Carter to Trump, share why recent actions put America’s health security at risk.

𝐍𝐞𝐰 𝐑𝐞𝐯𝐢𝐞𝐰 𝐀𝐫𝐭𝐢𝐜𝐥𝐞 𝐟𝐫𝐨𝐦 𝐄𝐮𝐠𝐞𝐧𝐞 𝐁𝐫𝐚𝐮𝐧𝐰𝐚𝐥𝐝, 𝐌𝐃: 𝐇𝐲𝐩𝐞𝐫𝐭𝐫𝐨𝐩𝐡𝐢𝐜 𝐂𝐚𝐫𝐝𝐢𝐨𝐦𝐲𝐨𝐩𝐚𝐭𝐡𝐲 (𝐇𝐂𝐌) Panel A shows the cardiac sarcomere, the repeating unit of contraction within cardiomyocytes. HCM-causing variants lead to a gain-of-function effect, shown in Panel B, which increases the proportion of cross-bridges in the active state and leads to adverse structural, energetic, and clinical consequences. Cardiac myosin inhibitors bind to myosin molecules and reduce their likelihood of being in the active state, thus attenuating hyper-contractility. Panel C shows normal myosin-actin cross-bridges (left) and increased cross-bridges and the effect of cardiac myosin inhibition in the presence of HCM (right). Learn more in the Review Article “Hypertrophic Cardiomyopathy” by Eugene Braunwald, MD, from @BrighamWomens and @harvardmed: nej.md/4n2pFWQ